Health Trials

About this trial

This is a observational, retrospective and prospective study designed to assess the potential correlations between MYC alterations, lymphoma mutational landscape and functional immune contextures in Diffuse Large B-cell Lymphoma or High-Grade B-cell Lymphoma

Eligibility criteria

Qualifiers

Diagnosis of nodal and extranodal Diffuse Large B Cell Lymphoma, High Grade B Cell Lymphomas (including low-grade transformed lymphomas; double and triple hit; 11q aberration; not otherwise specified) after 1st January 2019

Presence of one MYC translocation or gain of copies (GCN: > 3 copies in more than 30% of the nuclei) or amplification evaluated by FISH

Availability of immunohistochemical analysis of CD10, Bcl6, MUM1, Bcl2, Myc, Ki67

Have received curative treatment (e.g. R-CHOP, R DA EPOCH, intensified "Burkitt like" chemotherapies) as first-line therapy

Disqualifiers

Primary lymphomas of the central nervous system, plasmablastic lymphoma, Burkitt's lymphoma, primary mediastinal B lymphoma

Have received palliative treatment

Trial design

Treatments tested in this trial

  • Not listed

Trial groups

200 Participants
are grouped into 1 trial group

Locations

20
A.O.U. SS. Antonio e Biagio e C. Arrigo - S.C.D.U. Ematologia Alessandria Italy
A.O.U. Ospedali Riuniti delle Marche - Clinica di Ematologia Ancona Italy
I.R.C.C.S. Istituto Tumori Giovanni Paolo II - U.O.C. Ematologia Bari Italy
ASST Spedali Civili - S.C. Ematologia Brescia Italy

Sponsors and collaborators

Fondazione Italiana Linfomi - ETS

Lead sponsor

Source ClinicalTrials.gov